Publications by authors named "Cynthia Madden"
Article Synopsis
- Bimekizumab, a monoclonal antibody targeting IL-17F and IL-17A, is being tested as a treatment for moderate-to-severe hidradenitis suppurativa, a condition with limited treatment options.
- The BE HEARD I and II trials were 48-week, randomized, double-blind studies that evaluated the efficacy and safety of various dosing regimens of bimekizumab compared to a placebo in over 1,000 patients.
- Results showed significant improvement in patients receiving bimekizumab every 2 weeks, meeting the primary efficacy goal of at least a 50% reduction in disease symptoms by week 16.
Article Synopsis
- The study investigates the long-term safety of bimekizumab (BKZ) for patients with moderate-to-severe plaque psoriasis over three years, based on data from multiple trials.
- Out of 1,495 patients analyzed, the overall rate of treatment-emergent adverse events (TEAEs) was 175.5 per 100 patient-years, which decreased with longer treatment exposure.
- Common TEAEs included mild cases of nasopharyngitis and oral candidiasis, with serious adverse events remaining rare, indicating that BKZ's safety profile is stable over time.
Article Synopsis
- Discontinuation of biologic treatments in psoriasis is often due to ineffectiveness or side effects, leading to clinicians and patients considering switching therapies.
- The study evaluates the effectiveness and safety of switching to bimekizumab from three other biologics (adalimumab, ustekinumab, and secukinumab) over a period of up to 80 weeks.
- Results showed significant improvements in symptoms and quality of life for most patients who switched to bimekizumab, with a high percentage achieving substantial reductions in psoriasis severity, especially among those who initially did not respond well to their previous treatments.
Article Synopsis
- 1-year data showed bimekizumab's effectiveness exceeds that of adalimumab for treating moderate-to-severe plaque psoriasis, with safe outcomes.
- The BE SURE trial tested bimekizumab over 56 weeks, leading into the BE BRIGHT open-label extension for more extended safety and efficacy evaluation.
- By week 104, high PASI 90 (91.2% and 89.7%) and PASI 100 (72.3% and 68.1%) responses were seen with bimekizumab, while adalimumab patients also improved significantly after switching to bimekizumab.
Article Synopsis
- Bimekizumab is a monoclonal antibody that targets both interleukin-17A and interleukin-17F, and its effectiveness in treating moderate-to-severe plaque psoriasis compared to secukinumab (which targets only interleukin-17A) is unclear.
- In a phase 3b trial involving 743 patients, participants were assigned to receive either bimekizumab or secukinumab, and the main measure of success was a 100% reduction in the Psoriasis Area and Severity Index (PASI) score by week 16.
- Results showed that 61.7% of those on bimekizumab achieved PASI 100 by week 16,
Article Synopsis
- A phase 3 trial called BE VIVID evaluated the efficacy and safety of bimekizumab, a monoclonal antibody targeting IL-17F and IL-17A, compared to placebo and ustekinumab for treating moderate to severe plaque psoriasis over a 52-week period.
- The trial involved randomizing adults with significant psoriasis symptoms across multiple countries and included a total treatment regimen that permitted some patients to switch to bimekizumab after 16 weeks.
- Primary outcomes focused on achieving at least a 90% improvement in psoriasis severity and a clear or almost clear rating on a global assessment at the 16-week mark.
Article Synopsis
- Bimekizumab, a monoclonal IgG1 antibody targeting IL-17F and IL-17A, was studied for its effectiveness and safety in treating moderate to severe plaque psoriasis over 56 weeks.
- The BE READY trial involved 435 participants across nine countries and compared bimekizumab with a placebo to assess treatment outcomes based on specific measurement scales.
- Results showed that 91% of patients on bimekizumab achieved significant skin improvement (PASI90) by week 16, highlighting its potential as an effective treatment for psoriasis.
Article Synopsis
- The study investigated the long-term efficacy and safety of bimekizumab, a monoclonal antibody targeting both interleukin 17A and 17F, in treating moderate to severe psoriasis beyond the initial 12-week phase.
- Results indicated that patients who initially responded well maintained high levels of efficacy up to 60 weeks, with a significant percentage achieving complete skin clearance and few serious adverse events reported.
- Limitations included a small sample size for one of the dosages and the fact that most results were based on patients who had already shown a strong initial response.
Sports medicine, as a discipline, can be traced back to primitive man. The use of exercise as a prerequisite for conditioning and proper treatment of injuries was first documented in early Greek civilization with the establishment of the Olympics. Today, sports by their very nature invite injury.
View Article and Find Full Text PDF